Asian Journal of Pharmaceutical Research and Health Care

Open Access Open Access  Restricted Access Subscription Access

Biorelevant Dissolution Method Development for Dutasteride and Tamsulosin Hydrochloride Modified Release Capsule - A Prognostic Tool for Oral Drug Absorption


Affiliations
1 Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram – 608002, Tamil Nadu, India
2 Malla Reddy Pharmacy College, Maisammaguda, Hyderabad – 500014, Telengana, India
 

The research work was aimed to develop a biorelevant dissolution method for fixed dose combination containing Dutasteride 0.5 mg in immediate-release form and Tamsulosin 0.4 mg in modified-release form. Mean plasma concentration achieved after oral administration to human under pre-prandial condition are deconvoluted using Wagner-Nelson deconvolution method, to achieve target dissolution profile. The dissolution profile observed using office of generic drugs recommended dissolution media was observed to be faster than the target dissolution profile. Tamsulosin being a modified-release multiparticulate system, biorelevant dissolution method was developed with Fasted state simulated change over dissolution media, using USP Apparatus 3 (reciprocating cylinder). Dutasteride being an immediate-release form, dissolution method was developed with single dissolution media, by extending the dissolution run time upto Cmax. Dissolution media, media volume and Dips Per Minute (DPM) are optimized by performing full factorial design of experiment. The ANOVA result interprets the biorelevant dissolution media for Tamsulosin part is 250 ml of Fasted state simulated change over dissolution media with 15 DPM, based on desirability factor of 0.7768 and for Dutasteride part 250 ml of pH 6.5 Fasted state simulated intestinal fluids with 7 DPM, based on desirability factor of 0.8988. The regression co-efficient (R2) value of 0.999 and 0.996 demonstrates a very good in-vitro/in-vivo correlation under pre-prandial condition for Tamsulosin and Dutasteride respectively. The developed method shall be used as a predictive in-vitro tool for evaluation of in-vivo performance under pre-prandial condition.


Keywords

Deconvolution, Dutasteride, Pre-prandial, Tamsulosin
User
Notifications
Font Size

  • Miller J, Tarter TH. Combination therapy with Dutasteride and Tamsulosin for the treatment of symptomatic enlarged prostate. Clinical Interventions in Aging. 2009; 4: 251–8. 10.2147/CIA.S4102

  • US Food and Drug Administration, Silver Spring, MD 20993, Center for Drug Evaluation and Research, 2010, Printed Labelling for Jalyn (Dutasteride 0.5 mg/Tamsulosin hydrochloride 0.4 mg), 14th June 2010 [cited 2018 Apr 5]12https://www.accessdata.fda.gov/drugsatfda_docs/ nda/2010/022460Orig1s000LBL.pdf

  • Rashee K. Wagner-Nelson and numerical deconvolution based approaches for in-vivo performance prediction. International Journal of Science and Research. 2018; 7(8):1646–9.

  • Siewert M, Dressman J, Brown C, Shah V. AAPS guidelines for dissolution/in vitro release testing of novel/special dosage forms. Dissolution Technologies. 2003; 4:6–15.

  • Ramesh Babu B. Method development and validation for dissolution testings. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2011; 2(1):561–74.

  • Nikolay Z, Andre H, Leah X. First-principles and empirical approaches to predicting in-vitro dissolution for pharmaceutical formulation and process development and for product release testing. The American Association of Pharmaceutical Sciences. 2019; 21:32 DOI: 10.1208/ s12248-019-0297-y

  • Sandra K. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. The American Association of Pharmaceutical Sciences. 2010; 12(3):397– 406.

  • Raja S, Christopher V, Jayaveera. Analytical method development and validation of Dutasteride and Tamsulosin HCl in combination and its stress degradation studies. International Journal of Pharmacy and Analytical Research. 2013; 2(2):74–83.

  • Dendukuri VLN, Mrudula G, Prasad S, Rao PV. Simultaneous estimation and validation of Tamsulosin and Deutasteride in Bulk and Pharmaceutical dosage form. International Journal of Research in Pharmaceutical and Nano Sciences. 2014; 3(4):242–8.

  • Shivakumar Reddy L, Prasad Reddy SLN. Development and validation of a stability indicating liquid chromatographic method for simultaneous estimation of Dutasteride and Tamsulosin in combined dosage form. Oriental Journal of Chemistry. 2013; 29(4):1665–73.

  • Chiluba M, Khamanga SMM, Roderick BW. Development and assessment of a USP Apparatus 3 dissolution test method for sustained-release Nevirapine matrix tablets. Dissolution Technologies. 2016; 8:22–30.

  • Jantratid E, De V, Emanuela R, Valentina M, Maria V, Jennifer BD. Application of biorelevant dissolution tests to the prediction of in-vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. European Journal of Pharmaceutical Sciences. 2009; 37:434–41.

  • Ramalingam P, Kalva B. Analytical quality by design: A tool for regulatory flexibility and robust analytics. International Journal of Analytical Chemistry. 2015; (1): Article ID 868727. 9 pages, http://dx.doi.org/10.1155/2015/868727

  • Valery A, Fernando C, Maria FR, Gilberto B, Claudia A. Bioequivalence between two fixed dose combinations of Dutasteride and Tamsulosin in male subjects under fasting and fed conditions. International Annals of Medicine. 2017; 1(10). Available online from: https://doi.org/10.24087/ IAM.2017.1.10.346


Abstract Views: 274

PDF Views: 131




  • Biorelevant Dissolution Method Development for Dutasteride and Tamsulosin Hydrochloride Modified Release Capsule - A Prognostic Tool for Oral Drug Absorption

Abstract Views: 274  |  PDF Views: 131

Authors

Devi Thamizhanban
Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram – 608002, Tamil Nadu, India
Gampa Tulja Rani
Malla Reddy Pharmacy College, Maisammaguda, Hyderabad – 500014, Telengana, India
Kathiresan Krishnasamy
Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram – 608002, Tamil Nadu, India

Abstract


The research work was aimed to develop a biorelevant dissolution method for fixed dose combination containing Dutasteride 0.5 mg in immediate-release form and Tamsulosin 0.4 mg in modified-release form. Mean plasma concentration achieved after oral administration to human under pre-prandial condition are deconvoluted using Wagner-Nelson deconvolution method, to achieve target dissolution profile. The dissolution profile observed using office of generic drugs recommended dissolution media was observed to be faster than the target dissolution profile. Tamsulosin being a modified-release multiparticulate system, biorelevant dissolution method was developed with Fasted state simulated change over dissolution media, using USP Apparatus 3 (reciprocating cylinder). Dutasteride being an immediate-release form, dissolution method was developed with single dissolution media, by extending the dissolution run time upto Cmax. Dissolution media, media volume and Dips Per Minute (DPM) are optimized by performing full factorial design of experiment. The ANOVA result interprets the biorelevant dissolution media for Tamsulosin part is 250 ml of Fasted state simulated change over dissolution media with 15 DPM, based on desirability factor of 0.7768 and for Dutasteride part 250 ml of pH 6.5 Fasted state simulated intestinal fluids with 7 DPM, based on desirability factor of 0.8988. The regression co-efficient (R2) value of 0.999 and 0.996 demonstrates a very good in-vitro/in-vivo correlation under pre-prandial condition for Tamsulosin and Dutasteride respectively. The developed method shall be used as a predictive in-vitro tool for evaluation of in-vivo performance under pre-prandial condition.


Keywords


Deconvolution, Dutasteride, Pre-prandial, Tamsulosin

References





DOI: https://doi.org/10.18311/ajprhc%2F2020%2F25661